Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside

• Published in: Biomedicines Vol. 10; no. 10; p. 2512
• Main Authors: Liu, Xiaoli, Wang, Yifei, Chen, Bonan, Chan, Wai Nok, Mui, Chun Wai, Cheung, Alvin H.K, Zhang, Jinglin, Wong, Kit Yee, Yu, Jun, Kang, Wei, To, Ka Fai
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-10-2022; MDPI
• Subjects: Apoptosis; Care and treatment; Cell adhesion & migration; Cell cycle; Cell division; Cell growth; Cell proliferation; Cell survival; Gastric cancer; Hippo pathway; Kinases; Mammals; Medical prognosis; Metastases; Metastasis; Phosphorylation; Proteins; Review; Signal transduction; Solid tumors; Stomach cancer; TAZ (WW domain-containing transcription regulator 1); Tumor suppressor genes; Tumorigenesis; Tumors; YAP1 (yes-associated protein 1); United States
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10102512

The Hippo pathway is an evolutionally conserved signaling cascade that controls organ size and tissue regeneration under physiological conditions, and its aberrations have been well studied to promote tumor initiation and progression. Dysregulation of the Hippo tumor suppressor signaling frequently occurs in gastric cancer (GC) and other solid tumors and contributes to cancer development through modulating multiple aspects, including cell proliferation, survival, metastasis, and oncotherapy resistance. In the clinic, Hippo components also possess diagnostic and prognostic values for cancer patients. Considering its crucial role in driving tumorigenesis, targeting the Hippo pathway may greatly benefit developing novel cancer therapies. This review summarizes the current research progress regarding the core components and regulation of the Hippo pathway, as well as the mechanism and functional roles of their dysregulation in gastrointestinal malignancies, especially in GC, and discusses the therapeutic potential of targeting the Hippo pathway against cancers.